Prevention and transplantation in chronic kidney disease: What is achievable in emerging countries?

Nephron - Clinical Practice

Volumn 115, Issue 2, 2010, Pages

  Persy, Veerle P ^a   Remuzzi, Giuseppe ^b   Perico, Norberto ^b   Benghanem Gharbi, Mohammed ^c   Adu, Dwomoa ^d   Jha, Vivekanand ^e   Rizvi, Adib ^f   Ben Ammar, Mohamed ^g   Fongoro, Sahare ^h   De Broe, Marc E ⁱ  

^a Hugin Mugin Research   (Belgium)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

^c Hassan II Mohamedia University   (Morocco)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e Postgraduate Institute   (India)

^f SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

^g MONGI SLIM HOSPITAL   (Tunisia)

^h Point G Hospital   (Mali)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

CKD; Emerging countries; ESRD treatment; Prevention and transplantation; Renal disease; Screening and prevention; Transplantation programs in Africa

Indexed keywords

ACICLOVIR; ALBUMIN; AZATHIOPRINE; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DILTIAZEM; GANCICLOVIR; GENERIC DRUG; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

AFRICA; ARMENIA; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CADAVER DONOR; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONTINUING EDUCATION; COST CONTROL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE REGISTRY; DRUG COST; ENVIRONMENTAL FACTOR; GRAFT INFECTION; GRAFT SURVIVAL; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH PROGRAM; HEMODIALYSIS; HUMAN; INFORMATION DISSEMINATION; INTERNATIONAL COOPERATION; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER DISEASE; MEDICAL EXPERT; MEDICAL SOCIETY; MEDICOLEGAL ASPECT; NUTRITIONAL HEALTH; PAKISTAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SCREENING TEST; TECHNOLOGY; TRADITIONAL MEDICINE; URINALYSIS;

ACHIEVEMENT; DEVELOPING COUNTRIES; HUMANS; KIDNEY TRANSPLANTATION; MALI; RENAL INSUFFICIENCY, CHRONIC; WORLD HEALTH;

EID: 77951040371     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000312875     Document Type: Conference Paper

References (41)

1. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Nephrol Dial Transplant 2008; 23: 3375-3380.
2. Arogundade FA, Barsoum RS: CKD prevention in Sub-Saharan Africa: a call for governmental, non-governmental, and community support. Am J Kidney Dis 2008; 51: 515-523.
3. Bello AK, Nwankwo E, El Nahas AM: Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl 2005;S11-S17.
4. Mani MK: Experience with a program for prevention of chronic renal failure in India. Kidney Int Suppl 2005;S75-S78.
5. Hoy WE, Wang Z, Baker PR, Kelly AM: Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int Suppl 2003;S66-S73.
6. Hoy WE, Wang Z, Baker PR, Kelly AM: Secondary prevention of renal and cardiovascular disease: results of a renal and cardiovascular treatment program in an Australian Aboriginal community. J Am Soc Nephrol 2003; 14:S178-S185. (Pubitemid 36750515)
7. Masri MA, Haberal MA, Shaheen FA, et al: Middle East Society for Organ Transplantation (MESOT) Transplant Registry. Exp Clin Transplant 2004; 2: 217-220.
8. Rizvi SA, Naqvi SA, Hussain Z, et al: Renal transplantation in developing countries. Kidney Int Suppl 2003;S96-S100.
9. Najarian JS, Chavers BM, McHugh LE, Matas AJ: 20 years or more of follow-up of living kidney donors. Lancet 1992; 340: 807-810.
10. Ibrahim HN, Foley R, Tan L, et al: Long-term consequences of kidney donation. N Engl J Med 2009; 360: 459-469.
11. Kasiske BL, Ma JZ, Louis TA, Swan SK: Long-term effects of reduced renal mass in humans. Kidney Int 1995; 48: 814-819.
12. Narkun-Burgess DM, Nolan CR, Norman JE, et al: Forty-five year follow-up after uninephrectomy. Kidney Int 1993; 43: 1110-1115.
13. Torres VE, Offord KP, Anderson CF, et al: Blood pressure determinants in living-related renal allograft donors and their recipients. Kidney Int 1987; 31: 1383-1390.
14. Meier-Kriesche HU, Li S, Gruessner RW, et al: Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111-1131.
15. Sheashaa HA, Bakr MA, Fouda MA, et al: Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term followup. Int Urol Nephrol 2007; 39: 317-319.
16. Sheashaa HA, Bakr MA, Ismail AM, et al: Basiliximab induction therapy for live donor kidney transplantation: a long-term followup of prospective randomized controlled study. Clin Exp Nephrol 2008; 12: 376-381.
17. Sheashaa HA, Hamdy AF, Bakr MA, et al: Long-term evaluation of single bolus highdose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation. Int Urol Nephrol 2008; 40: 515-520.
18. Webster AC, Playford EG, Higgins G, et al: Interleukin-2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2004;CD003897.
19. Ghisdal L, Touchard G, Goujon JM, et al: First acute rejection episode after renal transplantation: study of the histopathological characteristics according to the immunological risk (in French). Nephrol Ther 2008; 4: 173-180.
20. Nashan B: Antibody induction therapy in renal transplant patients receiving calcineurin- inhibitor immunosuppressive regimens: a comparative review. Bio Drugs 2005; 19: 39-46.
21. Baquero A, Perez J, Rizik N, et al: Basiliximab: a comparative study between the use of the recommended two doses versus a single dose in living donor kidney transplantation. Transplant Proc 2006; 38: 909-910.
22. Remuzzi G, Lesti M, Gotti E, et al: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004; 364: 503-512.
23. Remuzzi G, Cravedi P, Costantini M, et al: Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow- up randomized, controlled clinical trial. J Am Soc Nephrol 2007; 18: 1973-1985.
24. Abramowicz D, Manas D, Lao M, et al: Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74: 1725-1734.
25. Jha V, Muthukumar T, Kohli HS, et al: Impact of cyclosporine withdrawal on living related renal transplants: a single-center experience. Am J Kidney Dis 2001; 37: 119-124.
26. Opelz G, Dohler B: Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year post-transplant. Transplantation 2008; 86: 371-376.
27. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, et al: Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365-1373.
28. Srinivas TR, Meier-Kriesche HU: Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008; 3(suppl 2):S101-S116.
29. Webster A, Woodroffe RC, Taylor RS, et al: Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005;CD003961.
30. Dominguez J, Kompatzki A, Foradori A, Norambuena R: Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection. Transplant Proc 2003; 35: 2522-2523.
31. Ingsathit A, Sumethkul V, Chalermsanyakorn P, Jirasiritham S: Co-administration of diltiazem and cyclosporine for kidney transplant recipients: a four-year follow-up study. J Med Assoc Thai 2006; 89(suppl 2):S235-S241.
32. Smith CL, Hampton EM, Pederson JA, et al: Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy 1994; 14: 471-481.
33. Carbajal H, Soltero L, Rodriguez-Montalvo C, Valdes A: Cyclosporine and low-dose ketoconazole in renal transplant recipients: a single-center experience. Transplantation 2004; 77: 1038-1040.
34. El-Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA: A prospective, randomized study of co-administration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. Transplantation 2004; 77: 1371-1376.
35. Abraham MA, Thomas PP, John GT, et al: Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients. Transplant Proc 2003; 35: 215-216.
36. El-Dahshan KF, Bakr MA, Donia AF, et al: Co-administration of ketoconazole to tacrolimus- treated kidney transplant recipients: a prospective randomized study. Nephrol Dial Transplant 2004; 19: 1613-1617.
37. Snyder JJ, Israni AK, Peng Y, et al: Rates of first infection following kidney transplant in the United States. Kidney Int 2009; 75: 317-326.
38. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: US Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, NIH, 2008.
39. Jha V: Post-transplantation infections: an ounce of prevention. Kidney Int 2009 (in press).
40. Reidenberg MM: Essential medicines for the whole world. Clin Pharmacol Ther 2007; 82: 500-503.
41. Fishman JA: Infection in renal transplant recipients. Semin Nephrol 2007; 27: 445-461.